A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Levis MJ, Perl AE, Schiller GJ, Fathi AT, Roboz GJ, Wang ES, Altman JK, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith CC.
Levis MJ, et al. Among authors: johansen m.
Blood Adv. 2024 Mar 19:bloodadvances.2023010619. doi: 10.1182/bloodadvances.2023010619. Online ahead of print.
Blood Adv. 2024.
PMID: 38502195